Table 2 |
|||
|
Pharmacological treatment of patients with systemic lupus erythematosus included in the study at the time the lumbar puncture was performed |
|||
| Treatment |
NPSLE (n = 43) |
No NPSLE (n = 71) |
aPL syndrome (n = 9) |
|
|
|||
| Prednisolone (≤10 mg) |
18 |
37 |
3 |
| Prednisolone (>10 mg) |
7 |
8 |
0 |
| No prednisolone |
18 |
23 |
5 |
| Antimalarials |
1 |
8 |
0 |
| Azathioprine |
5 |
10 |
3 |
| Azathioprine + cyclosporin A |
2 |
3 |
0 |
| Azathioprine + antimalarials |
0 |
0 |
0 |
| Methotrexate |
5 |
1 |
0 |
| Cyclosporin A |
0 |
6 |
1 |
| Cyclophosphamide |
14 |
10 |
0 |
| Cyclophosphamide + cyclosporin A |
3 |
0 |
0 |
| Cyclophosphamide + antimalarials |
0 |
1 |
0 |
| No cytotoxic drug |
11 |
30 |
4 |
| Antihypertensive treatment |
14 |
15 |
2 |
| Low-dose aspirin |
8 |
19 |
3 |
| Warfarin |
3 |
2 |
2 |
|
|
|||
|
aPL, antiphospholipid; NPSLE, neuropsychiatric involvement in systemic lupus erythematosus. |
|||
|
Trysberg et al. Arthritis Res Ther 2004 6:R551 doi:10.1186/ar1228 |
|||
